Cardiol Therapeutics (CRDL) Change in Net Loans (2021 - 2026)
Cardiol Therapeutics' (CRDL) quarterly Change in Net Loans came in at $10.8 million in Q1 2026, down 78.01% on a QoQ basis from $49.3 million in Q4 2021.
Cardiol Therapeutics (CRDL) Change in Net Loans (2021 - 2026) Analysis & Trends
Cardiol Therapeutics (CRDL) has 2 years of Change in Net Loans data on file, last reported at $10.8 million in Q1 2026.
- Quarterly Change in Net Loans changed N/A year-over-year to $10.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.1 million (changed N/A YoY) and the FY2021 annual result came in at $67.1 million, up 421.06% from the prior year.
- Change in Net Loans eased to $10.8 million in Q1 2026, from $49.3 million in the prior quarter.
- In the past five years, Change in Net Loans ranged from a high of $10.8 million in Q1 2026 to a low of $10.8 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Net Loans (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Cardiol Therapeutics | 211.60 Mn | 192.74 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.83 Mn |
| Dec 31, 2021 | 49.25 Mn |